Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia

Phase 1 Completed 13 enrolled Washington University School of Medicine Cephalon · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is designed to test the combination of decitabine, arsenic trioxide and ascorbic acid in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia

Timeline

Start: 2008-05
Primary completion: 2010-01
Completion: 2011-05

Publications

Welch JS, Klco JM, Gao F, Procknow E, Uy GL, Stockerl-Goldstein KE, Abboud CN, Westervelt P, DiPersio JF, Hassan A, Cashen AF, Vij R. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. Am J Hematol. 2011 Sep;86(9):796-800. doi: 10.1002/ajh.22092. Epub 2011 Aug 3. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Decitabine	Small molecule	20 mg/m2	Intravenous
Subject	arsenic trioxide	Small molecule	0.1 mg/kg	Intravenous
Subject	arsenic trioxide	Small molecule	0.2 mg/kg	Intravenous
Subject	arsenic trioxide	Small molecule	0.3 mg/kg	Intravenous

Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia

Summary

Timeline

Publications

Drugs

Indications